GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - DBV TECHNOLOGIES SA

Explicit Guidance:

• Financial Runway: Current cash runway extends through Q3 of the following year, covering all commercialization readiness investments and inventory build-up required for launch.
• Capital Access: Management indicates numerous financing tools are available as commercialization approaches; access to additional capital is anticipated if the "Breakthrough Therapy" designation results in "Priority Review," though no specific amounts, dates, or instruments are quantified.

Business-Segment Outlook:

• Regulatory Timeline (4–7 age group): BLA filed September 28; FDA review acceptance expected late November (approx. 60-day window). Full review timeline anticipated to be expedited due to Breakthrough Designation.
• Regulatory Timeline (1–3 age group): BLA filing timing to be finalized based on agency discussions to avoid review bottlenecks (FDA reviewing two BLAs in parallel); filing expected after learnings from the 4–7 submission.
• Commercial Launch Readiness: Supply chain and third-party logistics (3PL) and specialty pharmacy selection complete; inventory building initiated. Product availability expected "weeks after PDUFA" due to shipping from France (Amboise).
• Sales Force: 50–70 specialty sales representatives deployed to target allergists treating the 4–7 age cohort.
• Market Reach: Targeting 600,000 kids with peanut allergies (diagnosis codes and testing), with 54% of this population having concomitant food allergies.
• Treatment Protocol: Differentiated from competitors (e.g., Palforzia) via at-home immunotherapy (patch on back), eliminating the need for updosing visits to allergist sites.

Market and Competitive Outlook:

• Competitive Landscape (Zolair): Current market penetration estimated at ~1% of the target pediatric population; limited by the requirement for long-term selective immunosuppressant use and needle-based administration.
• Competitive Landscape (Palforzia): Limited to ~100 allergists performing OIT at scale; ViaSkin targets broader "community allergists" and allows parental administration at home.
• Demand Drivers: High unmet need driven by 80% persistence of peanut allergy into adulthood; 1 in 5 children in the 4–7 age range visit the ER annually for peanut reactions.
• Pricing Strategy: Not yet finalized; pricing will be informed by label specifics and ongoing payer value proposition discussions. Will leverage specialty pharmacy distribution and co-pay programs.
• Consumer Sentiment: Parents prioritize avoiding severe anaphylaxis and needle trauma; "daily patch" application is viewed as a significant value driver over oral immunotherapy burden.

Macro / Industry Outlook:

• Regulatory Environment: FDA engagement described as "fruitful" and "collaborative" regarding the novel CMC and biostats data structure for the BLA.
• Quality Systems: Addressing a previously issued Warning Letter at the manufacturing site (Amboise, France). Management expresses "high confidence" that issues (related to sterile manufacturing of a veterinary product, not the patch) will be resolved satisfactorily prior to Pre-Approval Inspection (PAI).
• Clinical Endpoints: Reliance on 1-year primary endpoint data (47% efficacy vs. 14% placebo) with expectations of continued efficacy gains in years 2–4, though specific long-term revenue projections tied to these durability data points are not provided.

Strategic Initiatives:

• Platform Expansion: ViaSkin platform initially focused on food allergy (peanut, milk, egg), with future potential applications for aero-allergens and other immunotherapies.
• Launch Strategy: Direct-to-consumer digital activation targeting parents via social media and advocacy groups; payer value proposition discussions ongoing to define reimbursement pathways.
• Patient Services: Building dedicated patient services elements and hub operations to support prior authorization and distribution.

Risks and Headwinds to Outlook:

• Regulatory Timing: Potential for FDA review bottlenecks given parallel review of two BLAs (1–3 and 4–7 age groups).
• Manufacturing Risk: The Warning Letter at the manufacturing site poses a risk of not being resolved in time for the pre-approval inspection; however, management deems this risk manageable.
• Clinical Uncertainty: Lack of efficacy data prior to 12 months of treatment; while early risk reduction (increase in eliciting dose) is observed at 3 months, specific protection thresholds at intermediate intervals (3–6 months) are not clinically validated.
• Adcom Uncertainty: While an Advisory Committee meeting is not currently expected, management acknowledges the FDA retains the right to convene one during the review cycle.

Management Tone on the Future:

• Confidence Level: High confidence in the resolution of the Warning Letter and the successful review of the BLA due to structured data and FDA collaboration.
• Strategic Hedging: Explicitly acknowledges the "bottleneck" risk regarding the second BLA submission and plans to file the 1–3 age indication in a manner convenient for the FDA.
• Commercial Readiness: Cautiously optimistic regarding launch timing ("weeks from PDUFA"), acknowledging logistics lead times while confirming supply chain and sales team readiness.

Miscellaneous:

• Clinical Data Highlights: 1-year pivotal data showed 47% efficacy (active) vs. 14% (placebo); 83% of ViaSkin-treated patients increased their eliciting dose, compared to 25% of untreated patients showing regression.
• Manufacturing Location: Product manufactured in Amboise, France; current plan involves third-party logistics for US distribution.
• Market Size Context: Only 10% of eligible children currently receive active treatment for peanut allergy.